Galatasaray sign Mauro Icardi from PSG – Former €100m star announced

By


French pay lion’s share of salary  

This article first appeared on September 7, 4:15 pm CET, and has since been updated with new information.

Mauro Icardi has left Paris Saint-Germain to join Galatasaray. On Wednesday, the centre-forward posted a picture of himself with a yellow and orange lion tattoo on his chest on Instagram, the colours of Gala, known as the Lions. Galatasaray made the loan move official on Thursday night. According to well-informed sources from Italy and Turkiye, PSG will nonetheless continue to pay the lion’s share of the salary. 

The clubs are said to have agreed that the 29-year-old will receive €3 million from Galatasaray and €5 million from PSG for the 2022/23 season, which he will spend on loan in Turkiye. At the Ligue 1 champions, who do not receive loan fee, his contract runs until 2024. Icardi no longer played a role under head coach Christophe Galtier and has been looking for a new opportunity.


Alli, Cakir & Co.
The most valuable Süper Lig players
Click here for overview
The former Inter Milan star will become the new most valuable player in the Süper Lig. Icardi’s current market value of €22 million, however, is only a fraction of the one he held in 2018. Like Dele Alli, who most recently joined Besiktas on loan from Everton, Icardi held a market value of €100 million at the end of 2018. Disagreements with Inter followed, then a €50 million move to PSG in 2019, and with it, less and less playing time. Icardi becomes Galatasaray’s ninth new signing of the summer.

Alli, Icardi & Co. – The most valuable players in 2018

New top earner: Icardi to compete with Mertens and Seferovic

Haris Seferovic (from Benfica) and Dries Mertens (from Napoli), who earn less than Icardi, were previously signed in the centre-forward position. While Mertens receives €2.9 million net per season, Severovic earns €2.3 million. New midfielder Sérgio Oliveira (from Porto) and Lucas Torreira (from Arsenal) each earn €2.75 million.


Homepage

 



Source link

Share This Article